SYDNEY, Australia, Nov. 15 /Xinhua-PRNewswire/ -- Pharmaceutical company
Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced the appointment of Dr
John Villiger as a new board director.
Dr Villiger brings strong international pharmaceutical development
experience to Pharmaxis, having created a successful NASDAQ-listed
pharmaceutical company and holding senior global roles at Roche.
"We are delighted to have John join our board," said Pharmaxis CEO Alan
Robertson. "His expertise in bringing products to market will be a valuable
complement to the existing Board members' skills."
Dr Villiger co-founded The Medicines Company in 1996, and was Senior
Vice President of Development until February this year. This business is
NASDAQ listed with market capitalisation of US$1.25 billion, 300 employees
and around US$220 million in projected 2006 sales.
Previously, Dr Villiger held various senior positions in product
development at Roche from 1986 to 1996 in New Zealand and Switzerland,
including International Project Director and Head of Global Project
Management. He oversaw the development of Roche's pharmaceutical portfolio,
managing over 50 development programs and teams in Switzerland, the UK, USA
and Japan. John has a PhD from the University of Otago and is widely
published.
"Pharmaxis is at the cusp of bringing significant advances in treating
respiratory diseases to patients worldwide," said Dr Villiger. "I look
forward to supporting this with the knowledge, experience and contacts I've
developed over the past 20 years in developing new medicines for global
markets."
Details on other Pharmaxis board directors can be found at
http://www.pharmaxis.com.au/investors/annual-reports/annual-reports_home.cfm
